日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies

ADCT-602,一种新型含 PBD 二聚体的抗体药物偶联物,用于治疗 CD22 阳性血液系统恶性肿瘤

Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A Hartley, Patrick

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers

ADCT-601 的临床前开发,这是一种新型基于吡咯并苯二氮卓二聚体的抗体药物偶联物,针对表达 AXL 的癌症

Francesca Zammarchi, Karin Eg Havenith, Simon Chivers, Paul Hogg, Francois Bertelli, Peter Tyrer, Narinder Janghra, Halla W Reinert, John A Hartley, Patrick H van Berkel

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease

针对心血管疾病中升高的脂蛋白 (a) 的新型 siRNA SLN360 的临床前毒理学评估

David Rider, Simon Chivers, Julia Aretz, Mona Eisermann, Kathrin Löffler, Judith Hauptmann, Eliot Morrison, Giles Campion

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

SG3199(抗体-药物偶联物 (ADC) 有效载荷 tesirine 的吡咯并苯二氮卓 (PBD) 二聚体弹头组分)的临床前药理学和作用机制

John A Hartley, Michael J Flynn, John P Bingham, Simon Corbett, Halla Reinert, Arnaud Tiberghien, Luke A Masterson, Dyeison Antonow, Lauren Adams, Sajidah Chowdhury, David G Williams, Shenlan Mao, Jay Harper, Carin E G Havenith, Francesca Zammarchi, Simon Chivers, Patrick H van Berkel, Philip W Howa